Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.

cortex meninges multiple sclerosis positron emission tomography translocator protein

Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
30 Jan 2024
Historique:
received: 21 09 2023
revised: 16 01 2024
accepted: 19 01 2024
medline: 30 1 2024
pubmed: 30 1 2024
entrez: 30 1 2024
Statut: aheadofprint

Résumé

Compartmentalized meningeal inflammation is thought to represent one of the key players in the pathogenesis of cortical demyelination in multiple sclerosis. Positron emission tomography targeting the 18 kDa mitochondrial Translocator Protein (TSPO) is a molecular-specific approach to quantify immune cell-mediated density in the cortico-meningeal tissue compartment in vivo. The aim of this study was to characterize cortical and meningeal TSPO expression in a heterogeneous cohort of multiple sclerosis cases using in vivo simultaneous MR-PET with 11C-PBR28, a second-generation TSPO radioligand, and ex vivo immunohistochemistry. Forty-nine multiple sclerosis patients (21 with secondary progressive and 28 with relapsing-remitting multiple sclerosis) with mixed or high affinity binding for 11C-PBR28 underwent 90-min 11C-PBR28 simultaneous MR-PET. Tracer binding was measured using 60-90 min normalized standardized uptake value ratio values sampled at mid-cortical depth and ∼3 mm above the pial surface. Data in multiple sclerosis patients were compared to 21 age-matched healthy controls. To characterize the nature of 11C-PBR28 PET uptake, the meningeal and cortical lesion cellular expression of TSPO was further described in post-mortem brain tissue from 20 cases with secondary progressive multiple sclerosis and five age-matched healthy donors. Relative to healthy controls, patients with multiple sclerosis exhibited abnormally increased TSPO signal in the cortex and meningeal tissue, diffusively in progressive disease and more localized in relapsing-remitting multiple sclerosis. In multiple sclerosis, increased meningeal TSPO levels were associated with increased Expanded Disability Status Scale scores (p = 0.007, by linear regression). Immunohistochemistry, validated using in-situ sequencing analysis, revealed increased TSPO expression in the meninges and adjacent subpial cortical lesions of post-mortem secondary progressive multiple sclerosis cases relative to control tissue. In these cases, increased TSPO expression was related to meningeal inflammation. Translocator Protein immunostaining was detected on meningeal major histocompatibility complex (MHC)-class II + macrophages and cortical activated MHC-class II + transmembrane protein (TMEM)119+ microglia. In vivo arterial blood data and neuropathology showed that endothelial binding did not significantly account for increased TSPO cortico-meningeal expression in multiple sclerosis. Our findings support the use of TSPO-PET in multiple sclerosis for imaging in vivo inflammation in the cortico-meningeal brain tissue compartment and provide in vivo evidence implicating meningeal inflammation in the pathogenesis of the disease.

Identifiants

pubmed: 38289855
pii: 7592489
doi: 10.1093/brain/awae030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Elena Herranz (E)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Harvard Medical School, Boston, MA 02115, USA.

Constantina A Treaba (CA)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Harvard Medical School, Boston, MA 02115, USA.

Valeria T Barletta (VT)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Harvard Medical School, Boston, MA 02115, USA.

Ambica Mehndiratta (A)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.

Russell Ouellette (R)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Karolinska Institutet, Department of Clinical Neuroscience, 141 86 Stockholm, Sweden.
Karolinska University Hospital, Department of Radiology, 141 86 Stockholm, Sweden.

Jacob A Sloane (JA)

Beth Israel Deaconess Medical Center, Department of Neurology, Boston, MA 02215, USA.

Carolina Ionete (C)

UMass Chan Medical School, Department of Neurology, Worcester, MA 01605, USA.

Suma Babu (S)

Harvard Medical School, Boston, MA 02115, USA.
Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.

Marina Mastantuono (M)

Neurology Section, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona 53593, Italy.
Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel 4058, Switzerland.

Stefano Magon (S)

Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel 4058, Switzerland.

Marco L Loggia (ML)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Harvard Medical School, Boston, MA 02115, USA.
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Meena M Makary (MM)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Harvard Medical School, Boston, MA 02115, USA.
Systems and Biomedical Engineering Department, Faculty of Engineering, Cairo University, Giza 12613, Egypt.

Jacob M Hooker (JM)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Harvard Medical School, Boston, MA 02115, USA.

Ciprian Catana (C)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Harvard Medical School, Boston, MA 02115, USA.

Revere Kinkel (R)

University of California San Diego, Department of Neuroscience, San Diego, CA 92093, USA.

Richard Nicholas (R)

Department of Brain Sciences, Faculty of Medicine, Imperial College London, London SW7 2BX, UK.

Eric C Klawiter (EC)

Harvard Medical School, Boston, MA 02115, USA.
Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.

Roberta Magliozzi (R)

Neurology Section, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona 53593, Italy.
Department of Brain Sciences, Faculty of Medicine, Imperial College London, London SW7 2BX, UK.

Caterina Mainero (C)

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charleston, MA 02129, USA.
Harvard Medical School, Boston, MA 02115, USA.

Classifications MeSH